Memorandum of Understanding between the Veterinary Medicines Directorate and the General Pharmaceutical Council

1. Introduction

1.1. This memorandum of understanding (MoU) outlines the basis of cooperation between the Veterinary Medicines Directorate (VMD) and the General Pharmaceutical Council (GPhC). It supports the GPhC’s role as the principal regulator responsible for inspections of registered pharmacies and pharmacy professionals.

1.2. The aims of this MoU are to:

- maintain safety for pharmacy users, the public and animals and safeguard animal welfare
- promote confidence in pharmacy services, including the supply of veterinary medicines
- support the sharing of information, intelligence, expertise and experience
- contribute to improving the regulatory oversight of pharmacy activities
- create the potential for reducing the burden of inspection activities in pharmacies
- define the circumstances in which the two organisations will act independently
- set out the responsibilities of the two parties in respect of the inspection of pharmacies and enforcement of the Veterinary Medicines Regulations (VMR).

1.3. This MoU is a statement of principle. The GPhC and VMD are already working together and more detailed operational protocols and guidance will be developed, as required. The VMD and the GPhC agree to adhere to the contents of this MoU. However, it is not intended to be a legally binding document. It does not override the organisations’ statutory responsibilities or functions, nor infringe the autonomy and accountability of the VMD and the GPhC or their governing bodies.

2. **Roles and responsibilities**

2.1. **The Veterinary Medicines Directorate**

2.2. The VMD is the competent authority for veterinary medicines in the UK and is an executive agency of the Department for Environment, Food and Rural Affairs (Defra).

2.3. The VMD’s aims are to safeguard public health, animal health and the environment and to promote animal welfare by ensuring the safety, quality and efficacy of all aspects of veterinary medicines in the UK.

2.4. Within the UK, the VMD is responsible for authorising the manufacture and supply of veterinary medicines, for monitoring suspected adverse events relating to veterinary medicines and for implementing the VMR.

2.5. The VMR are revoked and remade when the need is identified and so references to the VMR in this MoU mean those in force at the time. The VMD will discuss proposed changes to the VMR relating to the responsibilities of pharmacists and inspection of pharmacies with the GPhC before public consultation.

2.6. **The General Pharmaceutical Council**

The GPhC is the independent regulator for pharmacists, pharmacy technicians and pharmacy premises in England, Scotland and Wales. The functions of the GPhC are set out in the Pharmacy Order 2010 and include:

- setting standards for the education and training of pharmacists, pharmacy technicians and pharmacy support staff, and approving and accrediting their qualifications and training
- maintaining a register of pharmacists, pharmacy technicians and pharmacies
- setting the standards that pharmacy professionals have to meet throughout their careers
- investigating concerns that pharmacy professionals are not meeting the GPhC’s standards, and taking action to restrict their ability to practise when this is necessary to protect patients and the public or to uphold public confidence in pharmacy
- setting standards for registered pharmacies which require them to provide a safe and effective service to patients
- inspecting registered pharmacies to check if they are meeting our standards

In addition, the GPhC has enforcement powers and duties under the Poisons Act 1972, the Medicines Act 1968 and the VMR. These enforcement duties / powers mainly relate to the sale and supply of medicines from registered pharmacies.

2.7. The GPhC maintains an inspectorate. The GPhC’s inspectors inspect all registered pharmacies in Great Britain (GB) for the purpose of ensuring its standards are met and compliance with the relevant legislation that the GPhC enforces. In the case of pharmacies retailing veterinary medicines, the GPhC will assess compliance with the VMR, in particular the requirements referred to in Section 3 below.
2.8. The Secretary of State appoints inspectors under regulation 33 of the VMR for the purpose of enforcing those Regulations. Under regulation 36, in relation to a pharmacy, all the powers of an inspector to enforce those Regulations may also be exercised by an officer of the GPhC appointed for the purpose.

3. Retail Supply of veterinary medicines by pharmacists

3.1. The VMR (Schedule 3 paragraph 10) permits a registered pharmacist to retail supply veterinary medicines classified as POM-V, POM-VPS or NFA-VPS from:

   (a) premises registered as a pharmacy with the General Pharmaceutical Council or with the Pharmaceutical Society of Northern Ireland
   (b) premises registered with the Royal College of Veterinary Surgeons (RCVS) veterinary practice premises (VPPs)
   (c) premises approved by the Secretary of State for the storage and supply of veterinary medicines by suitably qualified persons (SQPs) (SQP retailers) in the case of a veterinary medicinal product classified as POM-VPS or NFA-VPS.

3.2. A pharmacist supplying a veterinary medicinal product (other than one classified as AVM-GSL) must be present when it is handed over unless the pharmacist:

   (a) authorises each transaction individually before the product is supplied; and
   (b) is satisfied that the person handing it over is competent to do so.

3.3. There are additional requirements for pharmacists supplying veterinary medicines (POM-V, POM-VPS and NFA-VPS) as set out in Schedule 3 of the VMR. In particular, pharmacists must comply with paragraphs 3, 5, 6, 7, 10, 11, 12, 13, 15, 22 and 23.

3.4. The VMD approves and inspects SQP retailer premises on behalf of the Secretary of State and inspects registered VPPs, other than those registered under the RCVS’s Practice Standards Scheme (PSS).

4. ‘Good manufacturing practice’ (GMP) and ‘good distribution practice’ (GDP: wholesaling):

4.1. A pharmacist who is appointed as a qualified person (QP) by a Manufacturing Authorisation (ManA) holder under Schedule 2 paragraph 9 of the VMR must comply with paragraph 11 of that Schedule.

4.2. A pharmacist who is specified as a wholesale dealer qualified person (WQP) by a wholesale dealer authorisation (WDA) holder under Schedule 3 paragraph 19 must ensure that the requirements of the WDA are complied with.
5. **Dealing with breaches of the VMR**

5.1. The VMD will deal with breaches of the VMR noted during its inspections, in accordance with its published [enforcement strategy](#).

5.2. Where a VMD inspector serves an improvement notice or a seizure notice on a pharmacist, or on a business due to the failure of a pharmacist to comply with the VMR (either fully or in part), the VMD will notify the GPhC when the notice is published.

5.3. The VMD will share more detailed information than is published when reasonably requested by the GPhC. Requests for information should be sent to the named contact.

5.4. If required and should circumstance arise, a GPhC inspector can serve an improvement notice or a seizure notice on a pharmacist, or on a pharmacy business, due to the failure of a pharmacist to comply with the VMR (either fully or in part). In which case, the GPhC will notify the VMD within 72 hours and send a copy of the notice to enable the VMD to publish the notice.

5.5. Failure to comply with an improvement notice may result in the person, on whom it was served, being prosecuted under the VMR. The VMD will inform the GPhC if any such prosecution is to be brought against a pharmacist.

5.6. The GPhC will deal with breaches of the VMR by registered pharmacists and pharmacy technicians through its Fitness to Practise procedures.

6. **Principles of co-operation**

6.1. The VMD and the GPhC intend that their working relationship will be characterised by the following principles:

- Making decisions that promote and protect pharmacy users, public safety, animal health and welfare and the environment in relation to veterinary medicines generally
- Sharing information, intelligence, expertise and experience
- Addressing overlaps and gaps in the regulatory framework
- Cooperating openly and transparently with the other organisation
- Respecting each other’s independent status
- Using resources effectively and efficiently.

Both organisations are committed to the more effective use of information, as a means to reducing the burden of regulation.

6.2. Details of key contacts within the VMD and the GPhC are contained in appendix A.
7. **Sharing information and intelligence**

7.1. If either organisation receives information (for example through professional whistleblowing or concerns raised by a member of the public) which:

- indicates a significant risk with regard to the supply of veterinary medicines, particularly in relation to the safety of pharmacy services or the conduct of a pharmacist or pharmacy technician
- is directly relevant to the delivery of the other organisation’s functions
- requires a coordinated multi-agency response
- reveals a pattern of information indicating a potential issue or concern

then this information will be shared in confidence with the named contact in the other organisation at the earliest possible opportunity, where relevant or necessary to support specific statutory functions, or in the public interest.

7.2. The GPhC routinely publishes information about the sanctions it has imposed on pharmacies and when pharmacists and pharmacy technicians are found to be not fit to practise. The GPhC also routinely publishes inspection reports on the outcomes of inspections of registered pharmacies as well as information about enforcement action imposed against pharmacies and pharmacy owners (since April 2019). This information is available through the GPhC’s website (and published in accordance with the GPhC’s publication and disclosure policy).

7.3. The GPhC will share more detailed information than is published when reasonably requested by the VMD. Requests for information should be sent to the named contact.

7.4. In pursuance of the parties’ statutory functions, including but not exclusively those contained in this MoU, information will be shared between them in accordance with the Information Commissioner’s Office data sharing code of practice, and their respective responsibilities under data protection legislation (including the Data Protection Act 2018 and the General Data Protection Regulation (EU 2016/679)), the Human Rights Act 1998 and the common law duty of confidentiality. If needed, a further GPhC VMD data sharing agreement will be developed by the two organisations.

7.5. Both parties will have appropriate technical and organisational security measures in place to protect any information that is shared. This will include making sure that information is secure in transit between the two organisations.

7.6. Both organisations recognise their respective responsibilities as data controllers under data protection legislation and as public bodies under the Freedom of Information Act 2000 (FOIA).

7.7. Where either party receives a request under the Freedom of Information Act, Data Protection Act, General Data Protection Regulation or other legislation, for information to be shared by the other, they will consult the party that provided the information before disclosing it. The parties acknowledge, though, that the final decision on disclosure rests with the party receiving the request.
7.8 Both parties agree to inform the other as soon as possible in the event of an incident or breach of confidentiality is discovered that impacts information shared by the other party.

8. **Sharing information - inspection of pharmacies**

8.1 The GPhC carries out unannounced inspections of registered pharmacies as a general rule (with some exceptions). Inspections are still planned in advance and undertaken by GPhC inspectors, who work in defined geographical areas. GPhC inspectors will share information about the inspections of pharmacies whose business primarily, or significantly, consists of supplies of veterinary medicines with the VMD and when relevant risks or concerns are identified in any registered pharmacy involving veterinary medicines.

8.2 The aims of sharing this information will be:
- to create an opportunity to alert inspectors to any relevant intelligence or information
- to avoid potentially unnecessary regulatory burden
- to facilitate a coordinated inspection and monitoring visit if this is deemed necessary
- to endeavour to provide support to the other organisation when requested.

8.3 Both parties will facilitate regular liaison between their inspectors, including conducting joint inspections or training, when necessary.

8.4 Whilst the VMD, as the national competent authority for veterinary medicines, may inspect pharmacies in relation to the manufacture or supply of veterinary medicines, it will make every effort to notify and collaborate with the GPhC before doing so. However, it is recognised that in some cases the VMD may conduct an inspection independently, in which case the VMD will inform the GPhC of the outcome of that inspection within 10 days.

9. **Sharing information - investigations**

9.1 Where either organisation intends to undertake an investigation which is relevant to the other organisation (over and above any routine inspection activity) a named contact in the other organisation should be alerted, in confidence, at the earliest possible opportunity.

9.2 Outcomes arising from any relevant investigations will be shared with a named contact at the earliest possible opportunity.

9.3 Where joint or parallel investigations are required, preliminary discussions should resolve any potential areas of conflict or overlap arising from the organisations’ respective powers.

9.4 The GPhC and the VMD will work towards developing a joint investigation framework for working together to help ensure efficient and effective joint investigations.

9.5 Where the VMD decides to undertake an investigation into, or bring criminal proceedings against, a registered pharmacist or person lawfully conducting a retail pharmacy business for an alleged breach of the VMR, it shall notify the GPhC as soon as is reasonably practicable.
10. Enforcement

10.1. Where either organisation has taken or intends to take enforcement action, the outcome of which is relevant to the other organisation, details will be shared at the earliest possible opportunity.

11. Governance

11.1. The effectiveness of the working relationship between the VMD and the GPhC will be ensured through regular contact, both formally and informally, at all levels up to and including chief executives of the respective organisations. Primary MoU contacts will meet at least once a year to discuss the MoU and the inspection of pharmacies, including consideration of compliance with the VMR by pharmacy professionals and registered pharmacies.

11.2. The GPhC and the VMD will monitor and review information shared and the impact of the MoU on a regular basis. In future, this may include the production of periodic monitoring reports that cover the frequency, or number, of interactions, the nature of the shared information and joint working and the impact that the cooperation of the two organisations has had.

11.3. The GPhC and the VMD are committed to holding shared learning opportunities for GPhC and VMD staff to increase awareness of the other organisation's objectives and responsibilities. In particular, the two organisations will work together to increase inspectors’ awareness and understanding of the requirements under the VMR, including their application during inspection.

11.4. Should any difficulties arise between the VMD and the GPhC these will normally be resolved at an operational level. If this is not possible, unresolved issues may be referred upwards through those responsible for operating this MoU, up to and including senior executives of each organisation, who will be jointly responsible for ensuring a mutually satisfactory resolution.

12. Duration and review

12.1. This MoU is not time-limited and will continue to have effect until the principles described need to be altered or cease to be relevant. The MoU may be reviewed more urgently at any time at the request of either party.

12.2. Both organisations have identified a person responsible for the management of this MoU in appendix A. They will liaise as required to ensure this MoU is kept up to date, identify any emerging issues and resolve any questions that arise in the working relationship between the two organisations.

12.3. This MoU will be reviewed at intervals of no greater than three years from the date of signing.

Duncan Rudkin
Chief Executive and Registrar
Signed on behalf of the GPhC
Date: 23 January 2020

Paul Green
Director of Operations
Signed on behalf of the VMD
Date: 30 January 2020